Month: January 2023

Myriad Genetics continues to advance non-invasive prenatal screening with Prequel®and the forthcoming FirstGene™ test using AMPLIFY™ technologySALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a recent guideline update by the American College of Medical Genetics and Genomics (ACMG), reaffirming the clinical value of non-invasive prenatal screening (NIPS) for a range of chromosomal abnormalities. Myriad is dedicated to advancing NIPS with best-in-class technology and important product launches. ACMG continues to recommend offering screening for common trisomies (on chromosomes 13, 18, and 21) in all pregnancies, and newly updated guidance now provides a strong recommendation for offering screening...

HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) — Freight Technologies, Inc. (Nasdaq: FRGT, Fr8Tech), a technology company developing solutions to optimize and automate the supply chain process and providing its Fr8App platform for B2B cross-border shipping in the USMCA region, announces guidance for revenue for 2023. The company projects 2023 revenue to be between $36 to $42 million, compared to preliminary 2022 revenue of approximately $26 to $27 million. Javier Selgas, CEO of Fr8Tech, said, “We look forward to continued growth in our cross-border and domestic FTL offerings over the course of the next 12 to 24 months and come into 2023 with a strong pipeline of existing customers and new prospects and growing lines of business. We are revising our guidance for 2023 revenues to be in the $36 to $42 million range as we continue to invest...

KRAKOW, Poland, Jan. 05, 2023 (GLOBE NEWSWIRE) — Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced that Pawel Przewiezlikowski, Chief Executive Officer of Ryvu Therapeutics, will participate in the Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel Discussion entitled “European Partners Dream Big, Make Bold Progress” on Wednesday, January 18, 2023, at 12:00 p.m. Eastern Time. Vatnak Vat-Ho, Chief Business Officer of Ryvu, will also participate in the 12th Annual LifeSci Partners Corporate Access Event, taking place January 9-11, 2023, in San Francisco, California. Details on the upcoming events are as follows:The Leukemia & Lymphoma Society Therapy Acceleration Program®...

NEW YORK, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced its appointment of an additional advisory board member to assist in the growth of the Company. Dr. T.Z. (Ted) Chaung, a seasoned independent healthcare consultant with broad experience in healthcare industry startups, new drug development, venture capital, and business development, in both the Taiwan and U.S. healthcare sectors, has joined the Company’s advisory board. “We are excited to welcome the addition of Dr. Ted Chaung to our Advisory Board,”  stated Hestia...

ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) —  Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced today that its end-of-Phase 2 meeting request with the U.S. Food and Drug Administration (“FDA”) to discuss advancing IMC-1 into Phase 3 development as a treatment for FM has been scheduled for mid-March 2023. At this meeting, the Company will discuss with the FDA plans for a Phase 3 program that would support submission of a new drug application for IMC-1 for the treatment of FM. The Company plans to provide a program update by the end of April following the receipt of formal written feedback from the FDA. The Company believes the safety and efficacy results from its...

Phase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two cohorts in 1H 2023 with interim data by end of 2023 Advancing solid tumor program with development of several TCRs for multiple HLAs across multiple targets; INDs filed for two MAGE-A1 TCRs (TSC-204-A0201 and TSC-204-C0702) as well as IND for multiplexing TCRs Cash runway funds operations into 2Q 2024 WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced its 2023 clinical pipeline plans and highlighted recent corporate achievements. “We made significant progress and growth in 2022, positioning both our solid tumor...

VANCOUVER, British Columbia, Jan. 05, 2023 (GLOBE NEWSWIRE) — American Lithium Corp. (“American Lithium” or the “Company”) (TSX-V:LI | OTCQB:LIACF | Frankfurt:5LA1) is pleased to announce it has received approval to list its common shares (the “Common Shares”) on the Nasdaq Capital Market (“Nasdaq”). Trading is scheduled to commence on Nasdaq at the open of markets on Tuesday January 10, 2023, under the symbol “AMLI”. Concurrently with the listing, the Common Shares will cease to be quoted on the OTCQB® Venture Market but will continue to trade on the TSX Venture Exchange. Simon Clarke, CEO of American Lithium stated, “We are very pleased to be joining Nasdaq as this listing marks a major milestone for the Company and is a testament to the dedication and hard work of our team. We are confident this listing will elevate American...

Thumzup Media Corporation The Thumzup mobile appAvailable in the App Store and Google Play, Thumzup Aims to Democratize the Social Media Branding Industry by Incentivizing Virtually Everyone to Post about Brands and Businesses through Major Social Media Outlets Los Angeles, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) — Thumzup Media Corporation (“Thumzup”) (OTCQB:TZUP) is excited to announce that its revolutionary platform, available in the App Store and Google Play, is aiming to democratize the $208 billion dollar advertising industry[1], similar to how Uber and Airbnb disrupted the transportation and hotel industries, respectively. The Thumzup mobile app, which is available for download in the App Store and Google Play, incentivizes virtually everyone to become social media advocates for the brands they enjoy by paying...

DENVER, Jan. 05, 2023 (GLOBE NEWSWIRE) — The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today reported financial results for the thirteen weeks ended November 26, 2022. First Quarter Summary:(1)Net sales increased 7.0% Net income(2) of $35.9 million versus $21.2 million Earnings per diluted share (“EPS”)(2) of $0.36 versus $0.22 Adjusted Diluted EPS(3) of $0.42 versus $0.43 Adjusted EBITDA(4) of $60.8 million versus $65.6 millionReaffirm fiscal year 2023 Net Sales and Adjusted EBITDA(4) outlook:Net sales expected to increase slightly greater than the Company’s long-term algorithm of 4-6%, including a headwind of almost 1 percentage point related to the frozen pizza licensing Adjusted EBITDA(4,5) anticipated...

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH DUBLIN, Ireland, and Boston MA, January 5, 2023, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce positive results from its APH-19 Phase 3 trial of lomitapide for the treatment of Homozygous Familial Hypercholesterolemia (HoFH) in children aged 5-17 years. Dr Joe Wiley, CEO of Amryt Pharma, commented: “We are encouraged by these important additional results regarding the efficacy of lomitapide in treating children with HoFH. This is good news for patients and their families.”   Top Line ResultsA total of 46 pediatric patients were enrolled, with 43 patients completing the run-in phase and entering the efficacy...